The session was addressed by Dr KP Singh, Senior consultant, Endocrinology who talked about the symptoms of diabetes, how the disease develops and its management strategies. Talking about how diabetes develops, Dr Singh said “Diabetes develops when glucose can’t enter the body’s cells to be used as fuel. This happens either because there is no key (insulin) to unlock the door or the cells – as in Type 1 diabetes – or because the key (insulin) is there but the lock doesn’t work properly, as in Type 2 diabetes. Without insulin, the body cannot get the blood glucose into the cells for energy. While Type 1 diabetes accounts for 5-10% of all diabetes diagnoses, Type 2 diabetes affects almost 90-95% of the patients.” Detailing the management strategies, “Type 2 diabetes happens a lot with obese people, but obesity is not that common among older diabetes patients. In nursing homes, the problem of being underweight is as common as that of being overweight. Thus, nutritional management should focus on weight gain for underweight elderly patients as much as it is focused on weight loss for obese patients.
For the original version including any supplementary images or video, visit http://timesofindia.indiatimes.com/city/chandigarh/Session-on-Management-of-Diabetes-in-Elderly-held-in-Chandigarh/articleshow/21803275.cms
Sanford-Burnham Collaborates With Pfizer to Identify Targets for Treatment of Insulin Resistance and Diabetes
13, 2013, 8:31 a.m. EDT Sanford-Burnham Collaborates With Pfizer to Identify Targets for Treatment of Insulin Resistance and Diabetes Collaboration Utilizes Sanford-Burnham Drug Discovery Platform to Find New Therapeutic Targets for Treating Complications of Obesity and Diabetes ORLANDO, FL, Aug 13, 2013 (Marketwired via COMTEX) — Sanford-Burnham Medical Research Institute (Sanford-Burnham) announced that it has entered into a collaboration with Pfizer Inc. to identify new therapeutic targets for preventing and treating complications of obesity and diabetes. The team will utilize novel screening tools including systems-biology approaches and technologies developed at Sanford-Burnham with the aim of discovering new therapeutic strategies for reducing insulin resistance in obesity and diabetes. Under the three-year agreement, multi-disciplinary teams from Sanford-Burnham and Pfizer will collaborate to identify and validate new targets for drug discovery.
For the original version including any supplementary images or video, visit http://www.marketwatch.com/story/sanford-burnham-collaborates-with-pfizer-to-identify-targets-for-treatment-of-insulin-resistance-and-diabetes-2013-08-13
Dance Biopharm Announces Encouraging Clinical Data for Adagio™– Inhalable Insulin Product Candidate for Diabetes
The company is actively engaged in discussions with the U.S. Food and Drug Administration (FDA) and is incorporating FDA input into clinical development plans for Adagio. Diabetes, A Global Epidemic Affecting an Estimated 347 Million People Worldwide There is a global epidemic of diabetes.The estimated 347 million people with diabetes worldwide is expected to grow to 439 million by 2030.For the majority of people with diabetes worldwide their disease is out of control and they will die prematurely.Metabolic disease may account for up to one third of healthcare costs in many regions of the world.Numerous studies have shown that better glucose control can extend life expectancy, improve quality of life, and markedly reduce the huge costs of managing diabetes and its complications. The long-term benefits of mealtime insulin therapy to control blood glucose have been consistently demonstrated. It is important to remember that exogenous insulin itself addresses both of the defects in Type 2 diabetes by improving endogenous insulin secretion (corrects insulin deficiency) and decreasing glucotoxicity and therefore decreasing insulin resistance.Many clinical studies have demonstrated that insulin not only preserves but can also restore b-cell function to the point of clinical remission in newly diagnosed Type 2 diabetics (Ryan et al, 2004; Li et al, 2004; Ilkova et al 1997, Alvarsson et al. 2003).Although injected insulin is the gold standard for treatment, traditionally it has been the last drug taken by Type 2 patients (who make up about 90-95 percent of diabetics).The typical patient delays taking mealtime insulin for five to 10 years in order to avoid multiple daily injections.Delaying insulin treatment, or refusing to take injections, eventually results in miserable health consequences for the patients and enormous costs to health care systems. Now all of the major diabetes medical associations recommend the introduction of insulin earlier in the treatment process for Type 2 patients, and if glycosylated hemoglobin (HbA1c) is above nine percent upon diagnosis and patients are symptomatic, insulin is recommended immediately.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/dance-biopharm-announces-encouraging-clinical-110000319.html